about
A randomized controlled trial of inhaled corticosteroids (ICS) on markers of epithelial-mesenchymal transition (EMT) in large airway samples in COPD: an exploratory proof of concept studyBasement membrane and vascular remodelling in smokers and chronic obstructive pulmonary disease: a cross-sectional study.Airway epithelial platelet-activating factor receptor expression is markedly upregulated in chronic obstructive pulmonary disease.Opposing effects of low molecular weight heparins on the release of inflammatory cytokines from peripheral blood mononuclear cells of asthmatics.Evaluation of epithelial mesenchymal transition in patients with chronic obstructive pulmonary diseaseIn-vitro suppression of IL-6 and IL-8 release from human pulmonary epithelial cells by non-anticoagulant fraction of enoxaparinNon-Anticoagulant Fractions of Enoxaparin Suppress Inflammatory Cytokine Release from Peripheral Blood Mononuclear Cells of Allergic Asthmatic Individuals.Orally Administered Enoxaparin Ameliorates Acute Colitis by Reducing Macrophage-Associated Inflammatory ResponsesEpithelial mesenchymal transition in smokers: large versus small airways and relation to airflow obstruction.Distinctive characteristics of bronchial reticular basement membrane and vessel remodelling in chronic obstructive pulmonary disease (COPD) and in asthma: they are not the same disease.Characterisation of colonic dysplasia-like epithelial atypia in murine colitis.Non-anticoagulant derivatives of heparin for the management of asthma: distant dream or close reality?Pathological changes in the COPD lung mesenchyme--novel lessons learned from in vitro and in vivo studies.Epithelial-mesenchymal transition as a fundamental underlying pathogenic process in COPD airways: fibrosis, remodeling and cancer.Chronic Obstructive Pulmonary Disease (COPD) and Lung Cancer: Epithelial Mesenchymal Transition (EMT), the Missing Link?Platelet activating factor receptor: gateway for bacterial chronic airway infection in chronic obstructive pulmonary disease and potential therapeutic target.Heparins in ulcerative colitis: proposed mechanisms of action and potential reasons for inconsistent clinical outcomes.An antagonist of the platelet-activating factor receptor inhibits adherence of both nontypeable Haemophilus influenzae and Streptococcus pneumoniae to cultured human bronchial epithelial cells exposed to cigarette smoke.Cigarette smoke and platelet-activating factor receptor dependent adhesion of Streptococcus pneumoniae to lower airway cells.Platelet-activating factor receptor (PAFr) is upregulated in small airways and alveoli of smokers and COPD patients.Ventilatory efficiency slope as a predictor of suitability for surgery in chronic obstructive pulmonary disease patients with lung cancer.Reticular basement membrane fragmentation and potential epithelial mesenchymal transition is exaggerated in the airways of smokers with chronic obstructive pulmonary disease.Reticular Basement Membrane Vessels Are Increased in COPD Bronchial Mucosa by Both Factor VIII and Collagen IV Immunostaining and Are Hyperpermeable.Endothelial to mesenchymal transition (EndMT): an active process in Chronic Obstructive Pulmonary Disease (COPD)?Role of epithelial mesenchymal transition (EMT) in chronic obstructive pulmonary disease (COPD).Epithelial mesenchymal transition (EMT) in small airways of COPD patients.Clinical significance of epithelial mesenchymal transition (EMT) in chronic obstructive pulmonary disease (COPD): potential target for prevention of airway fibrosis and lung cancer.Importance of epithelial mesenchymal transition (EMT) in COPD and asthma.Mast cells in COPD airways: relationship to bronchodilator responsiveness and angiogenesisIdentification of pro- and anti-proliferative oligosaccharides of heparins
P50
Q33705875-549BE279-7CBF-499F-B908-CD6BAAC04F5AQ34053645-42E015FF-F98C-4C0E-8A47-CFA1BFD4368BQ34065677-A121CFAF-CBBB-40C2-B589-D5B5CF1E186AQ35147247-1FF39EED-F1F2-4703-BEA0-750810326D8DQ35416133-66FA7926-C335-4A07-8B12-BB1E09F6928EQ35626866-E4CA5F33-83BC-4310-941D-79E46C4F0582Q35653704-21F50DB1-FD19-4B2A-82AC-E195B3A39D4BQ35719599-90E5902B-CBEE-497D-B5D5-1A4A588C24B4Q35935002-CB73C515-0629-4B36-A5AF-448047146C70Q36302003-D518ED61-74D8-46CC-8DF0-62155F8DEDBAQ37322447-26D559ED-1E3E-4660-B6B8-9F4A06F97C82Q38175433-116E828B-2DF1-46DF-9717-155C7AE19C4CQ38205679-19EA65C1-14B9-4F0F-8622-844FDB31CA93Q38238991-66649A8C-9CDC-4CA4-9FA9-59731F4D79E2Q38255396-6BDAF701-ABBE-4612-862A-2B540C8682CCQ38553473-409A5F3E-A5CA-40F8-8A54-655F3DB423F0Q38574126-866916CA-8B61-4EEF-83AF-FA6380A8F5C9Q38751856-B8E2866B-07E4-45F0-9F7A-E3801D03386DQ39355357-C6F43F30-30FB-41B0-B925-B85135DC1E97Q40873352-EC584CD7-A631-4A01-97AC-9854F67E1579Q42078991-1FBFDC7B-6A1F-474C-A36D-9A3A52BDA8EDQ42474300-D214065D-17E1-413C-9B76-2D1DDF80DADBQ42582268-B31C1661-D8AB-4BE3-874C-672F53FDE6F2Q42583668-EE5FD512-8912-4494-B0B0-E8CB7E9CD202Q42917103-11032A47-AABE-4DC0-8F54-8D2DC0898BB6Q43083414-63D87D25-7DD4-4772-9C57-4D2838ABF610Q43217503-734979B5-93C7-4992-952D-0C6B7C7B6575Q51722615-BAE1DEF0-EAE1-4014-82C2-0509AC88635BQ82243161-F491B637-901D-44D0-B1EC-008A35D24EDFQ86900135-CEE6589C-7330-46A5-9897-61EA1A2DAB39
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sukhwinder Singh Sohal
@ast
Sukhwinder Singh Sohal
@en
Sukhwinder Singh Sohal
@es
Sukhwinder Singh Sohal
@sl
type
label
Sukhwinder Singh Sohal
@ast
Sukhwinder Singh Sohal
@en
Sukhwinder Singh Sohal
@es
Sukhwinder Singh Sohal
@sl
prefLabel
Sukhwinder Singh Sohal
@ast
Sukhwinder Singh Sohal
@en
Sukhwinder Singh Sohal
@es
Sukhwinder Singh Sohal
@sl
P106
P31
P496
0000-0001-9627-6498